CN101528263B - 用于癌症的先天性免疫方法的缀合物 - Google Patents

用于癌症的先天性免疫方法的缀合物 Download PDF

Info

Publication number
CN101528263B
CN101528263B CN200780024865XA CN200780024865A CN101528263B CN 101528263 B CN101528263 B CN 101528263B CN 200780024865X A CN200780024865X A CN 200780024865XA CN 200780024865 A CN200780024865 A CN 200780024865A CN 101528263 B CN101528263 B CN 101528263B
Authority
CN
China
Prior art keywords
peptide
effector
cancer
linker
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200780024865XA
Other languages
English (en)
Chinese (zh)
Other versions
CN101528263A (zh
Inventor
安德烈·科尔特曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xintaibo Therapy Co Ltd
Original Assignee
Sku Asset Management Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sku Asset Management Co ltd filed Critical Sku Asset Management Co ltd
Publication of CN101528263A publication Critical patent/CN101528263A/zh
Application granted granted Critical
Publication of CN101528263B publication Critical patent/CN101528263B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN200780024865XA 2006-06-30 2007-07-02 用于癌症的先天性免疫方法的缀合物 Active CN101528263B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US80629806P 2006-06-30 2006-06-30
EP06013641 2006-06-30
EP06013640.5 2006-06-30
EP06013641.3 2006-06-30
US60/806,298 2006-06-30
EP06013640 2006-06-30
PCT/EP2007/005836 WO2008000517A2 (en) 2006-06-30 2007-07-02 Conjugates for innate immunotherapy of cancer

Publications (2)

Publication Number Publication Date
CN101528263A CN101528263A (zh) 2009-09-09
CN101528263B true CN101528263B (zh) 2013-01-23

Family

ID=38353353

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200780024865XA Active CN101528263B (zh) 2006-06-30 2007-07-02 用于癌症的先天性免疫方法的缀合物

Country Status (5)

Country Link
US (1) US8470963B2 (OSRAM)
EP (3) EP3669894A3 (OSRAM)
JP (3) JP2009541398A (OSRAM)
CN (1) CN101528263B (OSRAM)
WO (1) WO2008000517A2 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1986682B1 (en) * 2006-02-06 2013-08-28 The Burnham Institute for Medical Research Methods and compositions related to targeting tumors and wounds
CA2682580A1 (en) 2007-03-30 2008-10-09 Duke University A method of modulating the activity of a nucleic acid molecule
US20120010153A1 (en) 2009-01-14 2012-01-12 Andre Koltermann Novel tumor-targeting compounds
CN102639142A (zh) * 2009-09-16 2012-08-15 杜克大学 内体Toll样受体活化的抑制
JP2015513358A (ja) * 2012-03-22 2015-05-11 ザ キュレイターズ オブ ザ ユニバーシティ オブ ミズーリ 金結合性及びｅｇｆｒ受容体親和性を有するペプチド、並びに金ナノ構造に結合したペプチド
US10066323B2 (en) 2014-04-16 2018-09-04 Duke University Electrospun cationic nanofibers and methods of making and using the same
GB201609083D0 (en) * 2016-05-24 2016-07-06 Syntab Therapeutics Gmbh Synthetic compound
US12447464B2 (en) 2016-12-22 2025-10-21 Duke University Polycationic microfibers and methods of using the same
US20200155702A1 (en) * 2017-06-16 2020-05-21 Eli Lilly And Company Engineered Antibody Compounds and Conjuates Thereof
WO2020018941A1 (en) * 2018-07-19 2020-01-23 The Regents Of The University Of California Peptides for activation of cell signaling in osteoprogenitor cells
CN109055476B (zh) * 2018-08-07 2021-07-09 河南大学 一种生物活性肽p11在治疗甲状腺癌的药物中效果分析方法
CN109679981A (zh) * 2019-02-21 2019-04-26 武汉大学 一种甲酰基肽定向进化噬菌体及其制备方法与应用
CN111474370B (zh) * 2020-04-22 2021-04-06 天津医科大学总医院 检测甲酰肽或甲酰肽受体-1配体含量的方法及应用
US20240050582A1 (en) * 2021-03-08 2024-02-15 Universiteit Gent Conjugates including multiple saccharidic chains on a linear protein and uses in mammals feed
CN115448980A (zh) * 2021-06-08 2022-12-09 戴德森医疗财团法人嘉义基督教医院 表面链结标靶多肽的类病毒颗粒及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427660A (en) * 1982-03-03 1984-01-24 Research Corporation Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1055932A (en) 1975-10-22 1979-06-05 Hematech Inc. Blood substitute based on hemoglobin
IT1164225B (it) 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
US5580563A (en) * 1992-05-01 1996-12-03 Tam; James P. Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof
US5767078A (en) 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
PL185040B1 (pl) 1995-06-07 2003-02-28 Affymax Tech Nv Peptyd wiążący się z receptorami erytropoetyny, kompozycja farmaceutyczna zawierająca ten peptyd i jego zastosowanie do wytwarzania środka leczniczego
DE19853778C1 (de) 1998-11-21 2000-09-21 Basf Ag DNA-Sequenzen kodierend einen Glutamat/Malat-Translokator, Plasmide Bakterien, Hefen und Pflanzen enthaltend diesen Transporter
AU2030000A (en) 1998-11-25 2000-06-13 Cadus Pharmaceutical Corporation Methods and compositions for identifying receptor effectors
US6017537A (en) * 1998-12-18 2000-01-25 Connaught Laboratories, Inc. Formyl methionyl peptide vaccine adjuvant
US20030099629A1 (en) * 1999-03-11 2003-05-29 Immunomedics, Inc. Recombinant onconase and chemical conjugates and fusion proteins of recombinant onconase
US6703480B1 (en) 1999-11-24 2004-03-09 Palani Balu Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
CN1318084C (zh) 2000-05-26 2007-05-30 奥索-麦克尼尔药品公司 神经保护肽
ATE500277T1 (de) 2001-01-16 2011-03-15 Univ Ramot Hybridpeptide für die behandlung von bacteraemie und sepsis
US7265084B2 (en) * 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
WO2004000802A2 (en) * 2002-06-20 2003-12-31 University Of Maryland Biotechnology Institute Scaffolded maleimide clusters for multivalent peptide assembly
KR101045401B1 (ko) 2002-09-11 2011-06-30 프레제니우스 카비 도이치란트 게엠베하 하이드록시알킬 전분 유도체
EP1626983B8 (en) 2003-05-12 2010-12-22 Affymax, Inc. Novel poly (ethylene glycol) modified erythropoietin agonists and uses thereof
WO2004101611A2 (en) 2003-05-12 2004-11-25 Affymax, Inc. Peptides that bind to the erythropoietin receptor
UA88146C2 (ru) 2003-05-12 2009-09-25 Афимакс, Инк. Новые пептиды, которые связываются с рецептором эритропоэтина
US7919118B2 (en) 2003-05-12 2011-04-05 Affymax, Inc. Spacer moiety for poly (ethylene glycol) modified peptide based compounds
EP1538164A1 (en) * 2003-12-04 2005-06-08 Vectron Therapeutics AG RGD targeting moiety its production and use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427660A (en) * 1982-03-03 1984-01-24 Research Corporation Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Hetland G et al..Effect of formyl peptide-toxin conjugates on myeloid cancer cell lines in vitro.《InternationalJournal of Immunotherapy》.1995,第11卷(第3期),第85-93页. *
Li ZongHai et al..Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics.《The FASEB Journal》.2005,第19卷(第14期),第1978-1985页. *
Obrist R et al..Chemotactic monoclonal antibody conjugates a comparison of four different F-Methionine-Peptide Conjugates.《Biochemical and Biophysical Research Communications》.1988,第155卷(第3期),第1139-1144页. *
Obrist R et al..Monocyte chemotaxis mediated by formyl-methionyl-leucyl-phenylalanine conjugated with monoclonal antibodies against human ovarian carcinoma.《International Journal of Immunopharmacology》.1983,第5卷(第4期),第307-314页. *
Rabiet M-J et al..Human mitochondria-derived N-formylated peptides are novel agonists equally active on FPR and FPRL1,while Listeria monocytogenes-derived peptides preferentially activate FPR.《European Jorunal of Immunology》.2005,第35卷(第8期),第2486-2495页. *
RabietM-Jetal..Humanmitochondria-derivedN-formylatedpeptidesarenovelagonistsequallyactiveonFPRandFPRL1 while Listeria monocytogenes-derived peptides preferentially activate FPR.《European Jorunal of Immunology》.2005
Reto Obrist et al..Enhancement of macrophage invasion of tumorss by administration of chemotactic factor-antitumor antibody conjugates.《Cellular Immunology》.1983,第81卷(第1期),第169-174页. *

Also Published As

Publication number Publication date
EP3669894A3 (en) 2020-08-26
CN101528263A (zh) 2009-09-09
EP2035041B1 (en) 2020-01-08
JP2009541398A (ja) 2009-11-26
US8470963B2 (en) 2013-06-25
WO2008000517A2 (en) 2008-01-03
EP2035041A2 (en) 2009-03-18
US20100233161A1 (en) 2010-09-16
JP2017002039A (ja) 2017-01-05
EP3669894A2 (en) 2020-06-24
WO2008000517A3 (en) 2009-04-02
EP2275142A2 (en) 2011-01-19
EP2275142A3 (en) 2011-05-11
JP2014166186A (ja) 2014-09-11

Similar Documents

Publication Publication Date Title
CN101528263B (zh) 用于癌症的先天性免疫方法的缀合物
Li et al. Chemically modified and conjugated antimicrobial peptides against superbugs
TWI250988B (en) Thrombopoietic compounds
US7592009B2 (en) Polypeptide ligands for targeting cartilage and methods of use thereof
Ngambenjawong et al. Synthesis and evaluation of multivalent M2pep peptides for targeting alternatively activated M2 macrophages
US10202421B2 (en) Tumor-targeting compounds
WO2012090150A2 (en) New cell-penetrating peptides and uses thereof
JP2001512739A (ja) 抗生作用ペプチドから誘導される線状ペプチド、製法および活性物質を仲介する用途
CN101146822A (zh) EphB受体结合肽
CN111093718A (zh) 治疗性纳米缀合物及其用途
US20220226486A1 (en) Synthetic compound
CN115811990B (zh) 新型核仁素结合肽及其应用
Uray et al. Synthesis and receptor binding of IgG1 peptides derived from the IgG Fc region
Pola et al. Polymer—Doxorubicin Conjugate with a Synthetic Peptide Ligand Targeted on Prostate Tumor
JP3819712B2 (ja) 細胞内信号伝達を攪乱させる合成ペプチド
CN113597318A (zh) 治疗性纳米缀合物及其用途
WO2025262329A1 (en) Synthetic molecules comprising tlr2 ligands
WO2010111910A1 (zh) 一种合成肽及其应用
HK40006607A (en) Synthetic compound
CN116507364A (zh) 组合物
RoyChowdhury Synthesis and biological evaluations of peptidoglycan part structures

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: SKU ASSET MANAGEMENT LTD.

Free format text: FORMER OWNER: KOLTERMANN ANDRE

Effective date: 20121130

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20121130

Address after: Baierbrunn, Germany

Applicant after: SKU Asset Management Co., Ltd.

Address before: Iran, Germany

Applicant before: Koltermann Andre

C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20190221

Address after: Nashville, Germany

Patentee after: Xintaibo Therapy Co., Ltd.

Address before: Baierbrunn, Germany

Patentee before: SKU Asset Management Co., Ltd.

TR01 Transfer of patent right